The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans

Autor: S Schober-Bendixen, Wolfgang Mundt, Friedrich Dorner, Manfred Reiter, Noel Barrett, Helga Savidis-Dacho, John Aaskov, Axel Brühmann, Otfried Kistner
Rok vydání: 2006
Předmět:
Epidemic polyarthritis
medicine.medical_treatment
Guinea Pigs
Drug Evaluation
Preclinical
Enzyme-Linked Immunosorbent Assay
Viral Plaque Assay
Antibodies
Viral
Neutralization
Virus
Microbiology
Ross River virus
Viral Proteins
Adjuvants
Immunologic
Formaldehyde
Chlorocebus aethiops
medicine
Animals
Humans
Vero Cells
060502 Infectious Agents
ihb
General Veterinary
General Immunology and Microbiology
biology
Alphavirus Infections
Public Health
Environmental and Occupational Health
Viral Vaccines
biology.organism_classification
medicine.disease
Virology
Microscopy
Electron
Infectious Diseases
Immunization
Immunoglobulin M
Vaccines
Inactivated
cells and tissue
biology.protein
Vero cell
Molecular Medicine
Polyarthritis
Electrophoresis
Polyacrylamide Gel
060599 Microbiology not elsewhere classified
Antibody
Vaccine
Adjuvant
Zdroj: Vaccine
ISSN: 0264-410X
Popis: Ross River virus was grown in industrial facilities in vaccine-certified Vero cells in the absence of serum, inactivated using standard formalin-inactivation protocols, treated with Benzonase to digest host cell DNA and purified on a sucrose gradient. Mice given two subcutaneous injections of 0.625 microg of this vaccine or two doses of 0.156 microg vaccine with aluminium hydroxide adjuvant failed to develop a detectable viraemia after intravenous challenge with 10(6)TCID50 of the prototype strain of Ross River virus (T48). Guinea pigs immunised with one or two10 microg doses of vaccine with adjuvant also failed to develop a detectable viraemia following a similar challenge. The levels of neutralising antibody (neutralisation index 1.9-3.1) in the mice protected against challenge with 10(6)TCID50 Ross River virus were similar to those in 16 former epidemic polyarthritis patients (1.1-3.5) who had not experienced a second clinical infection with Ross River virus in the 20 years following their initial infection.
Databáze: OpenAIRE
Externí odkaz: